You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2025 › July › 29
Merck
11 months ago
US drugmaker reports 17% fall in net income to $4.4bn in the second quarter
Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook ○
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.
page 1 of 1